oncnursingnews6h
How to Overcome 4 Common Barriers to Cancer Clinical Trial Access
An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and ...
oncnursingnews1d
FDA Delays Decision Date for Zenocutuzumab in Lung, Pancreatic Cancer
The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of ...
oncnursingnews2d
John Sweetenham, MD, FACP, FRCP
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews2d
ERIC BLACKSTONE, MA
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews2d
Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer
The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.
oncnursingnews3d
Julie Huynh, MS
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews3d
Samantha Stephens
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews3d
Kristina Davis
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews3d
Genny's Hope
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews3d
Hope Haefner, MD
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews3d
Nicole Nelson
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...
oncnursingnews3d
Frank delaRama, RN, MSN, AOCNS
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma ...